Home > Cardiology > ACC 2022 > Heart Failure and Cardiomyopathy > Replacing septal reduction therapy with mavacamten for HCM

Replacing septal reduction therapy with mavacamten for HCM

Presented By
Prof. Milind Desai, Cleveland Clinic, USA
Conference
ACC 2022
Trial
Phase 3, VALOR-HCM
Initial data from the VALOR-HCM trial indicated that targeted therapy for hypertrophic cardiomyopathy (HCM) with mavacamten, a small molecule inhibitor of β-cardiac myosin, is likely to be the new standard of care. Prof. Milind Desai (Cleveland Clinic, OH, USA) presented the first findings from the multicentre, double-blind, placebo-controlled, randomised, phase 3 VALOR-HCM (NCT04349072) trial [1,2]. The primary endpoint was a composite of the patient’s preference to proceed with septal reduction therapy (SRT) before the end of week 16 or remain guideline-eligible for SRT at week 16. Secondary efficacy endpoints included change from baseline to week 16 in post-exercise left ventricular outflow tract obstruction (LVOT), New York Heart Association (NYHA) Classification, Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, and cardiac troponin. Th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on